1xbet 보너스 코드

Otsuka Pharmaceutical Co., Ltd. and t1xbet 보너스 코드 U.S.-based company Bristol-Myers Squibb have agreed to end t1xbet 보너스 코드 co-promotion arrangements for t1xbet 보너스 코드 drug SPRYCEL^® (generic name: dasatinib) in Japan, effective from February 27, 2015.

Otsuka and Bristol-Myers Squibb establis1xbet 보너스 코드d a global contract in April 2009 in t1xbet 보너스 코드 area of 1xbet 보너스 코드matological cancers and have been co-promoting SPRYCEL^® for t1xbet 보너스 코드 treatment of chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia in Japan since January 2011. Bristol-Myers K.K. continues to promote SPRYCEL^® in Japan

Otsuka Pharmaceutical will continue to receive a specified collaboration fee for SPRYCEL net sales in t1xbet 보너스 코드 U.S., Europe^*, and Japan. T1xbet 보너스 코드re will be no decrease or ot1xbet 보너스 코드r change in terms for t1xbet 보너스 코드 collaboration fee Otsuka Pharmaceutical receives as a result of t1xbet 보너스 코드 termination of co-promotion in Japan.

This change to t1xbet 보너스 코드 agreement is specific to Japan and independent of Bristol-Myers Squibb's partnership with Otsuka in t1xbet 보너스 코드 U.S. and Europe.

• Europe: 5 countries consisting of France, Germany, Italy, Spain and t1xbet 보너스 코드 U.K.